MB-IMP

Phase 2Small molecule

SSouthwest Autism Research & Resource Center

MB-IMP is one of 25 small molecule programs targeting Anxiety. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnxietyActive, not recruiting

AnxietyPhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Anxiety

#DrugCompanyPhaseTrials

Duragesic

CCephalon

Phase 3

1 2

Centanafadine

Otsuka

Phase 3

1 3

Celexa

AbbVie

Preclinical

1 4

Spravato

WWim Janssens

Preclinical

4 5

Campral

FForest Laboratories

Preclinical

2 6

Luvox

SSolvay Pharmaceuticals

Preclinical

2 7

Anerem

AAcacia Pharma Ltd

Preclinical

2 8

Andriol

AAuxilium

Preclinical

1 9

Intelence

WWim Janssens

Preclinical

1 10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Anxiety

NCT06526208

Clinical

Trials by Indication[1]

Anxiety1 trial

Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

Not yet recruiting·SSouthwest Autism Research & Resource Center·Phase 2·NCT06526208·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MB-IMP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MB-IMP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MB-IMP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Southwest Autism Research & Resource Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSouthwest Autism Research & Resource Center

MB-IMP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Anxiety1 trial

References

Drug Info

Quick Facts

Related News